<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bone physiology and biochemical markers of bone turnover</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bone physiology and biochemical markers of bone turnover</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bone physiology and biochemical markers of bone turnover</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold N Rosen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In adults, bone is constantly being remodeled, first being torn down (bone resorption) and then being rebuilt (bone formation) [<a href="#rid1">1,2</a>]. The resorption and reformation of bone is important for repair of microfractures and to allow modification of structure in response to stress and other biomechanical forces. Bone formation is normally tightly coupled to bone resorption, so that bone mass does not change. Bone diseases occur when formation and resorption are uncoupled. (See  <a class="medical medical_review" href="/z/d/html/2053.html" rel="external">"Normal skeletal development and regulation of bone formation and resorption"</a>.)</p><p>Changes in the rate of bone turnover are an important determinant of bone disease, and therefore, measurements that correlate with the rate of turnover provide important information in assessing patients with bone disease. In the past, the best way to measure bone turnover was to perform a bone biopsy after double-labeling with <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> [<a href="#rid1">1,3</a>]. This technique permits measurement of the rates of bone formation and bone resorption, and the fractions of bone surface at which active resorption and formation are ongoing. However, the complexity and expense of this procedure make it unsuitable for routine clinical practice.</p><p>As an alternative, several assays are currently available that measure bone turnover markers (BTMs)  (<a class="graphic graphic_table graphicRef77322" href="/z/d/graphic/77322.html" rel="external">table 1</a>). These assays measure collagen breakdown products and other molecules released from osteoclasts and osteoblasts during the process of bone resorption and formation. Although the development of better assays has improved the ability of BTMs to reflect the rate of bone turnover, biologic and laboratory variability have confounded their widespread use in clinical practice.</p><p>This topic will review bone physiology and the measurement of BTMs. The clinical utility of BTMs is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2041.html" rel="external">"Use of biochemical markers of bone turnover in osteoporosis"</a> and  <a class="medical medical_review" href="/z/d/html/7488.html" rel="external">"Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">BONE REMODELING</span><span class="headingEndMark"> — </span>The steps involved in bone formation and resorption are described briefly here and in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2053.html" rel="external">"Normal skeletal development and regulation of bone formation and resorption"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Bone resorption</span><span class="headingEndMark"> — </span>Bone resorption is initiated by osteoclasts, which are derived from hematopoietic stem cells [<a href="#rid4">4</a>] and have acid phosphatase anchored to their cell membranes [<a href="#rid2">2,5</a>]. Although acid phosphatase activity is present in other tissues such as the prostate gland, the two forms of the enzyme can be distinguished by the insensitivity of osteoclastic acid phosphatase to inhibition by tartrate (tartrate-resistant acid phosphatase, TRAP).</p><p>The osteoclasts attach to the bone surface and secrete acid and hydrolytic enzymes that resorb bone, releasing bone minerals and fragments of collagen. Some of the collagen is completely digested to its smallest chemical units, resulting in formation of free pyridinoline and deoxypyridinoline residues that circulate in the blood and are excreted in the urine. Some, however, is incompletely digested, resulting in formation in pyridinoline crosslinks bound to fragments of the alpha-1 and alpha-2 chains; these peptide-bound crosslinks also circulate in the blood and are excreted in the urine [<a href="#rid5">5-7</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Bone formation</span><span class="headingEndMark"> — </span>Bone formation is initiated by osteoblasts, which synthesize type I collagen and other proteins, such as osteocalcin, that combine extracellularly to form osteoid, the organic substrate upon which mineralization occurs [<a href="#rid2">2</a>]. The osteoblasts contain alkaline phosphatase anchored to their cell membranes. This alkaline phosphatase is functionally similar to but antigenically distinct from hepatic and placental alkaline phosphatases [<a href="#rid8">8</a>].</p><p>The synthesis of type I collagen in bone involves the intertwining of one alpha-2 and two alpha-1 polypeptide chains to form a helical structure known as procollagen, followed by cleavage of their amino-terminal and carboxy-terminal peptides to form tropocollagen  (<a class="graphic graphic_figure graphicRef77562" href="/z/d/graphic/77562.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>]. Tropocollagen is mainly helical; the nonhelical portions at the amino and carboxy terminals are known as the N-telopeptide and C-telopeptide regions, respectively.</p><p>The side chains of three hydroxylysine residues from different tropocollagen molecules condense to form a pyridinium ring, thereby forming the pyridinoline crosslinks (PYD) that connect three different tropocollagen molecules [<a href="#rid1">1,9</a>]. A deoxypyridinoline (D-PYR) crosslink is a variant form of the pyridinoline crosslink that is formed when two hydroxylysine side chains condense with one lysine side chain [<a href="#rid10">10</a>]. Pyridinoline crosslinks also occur in many types of collagen outside of bone except for collagen in skin [<a href="#rid10">10,11</a>].</p><p>There are three types of pyridinoline crosslinks that are characteristic of bone collagen  (<a class="graphic graphic_figure graphicRef60367" href="/z/d/graphic/60367.html" rel="external">figure 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>D-PYR is present in substantial amounts only in bone and in dentin [<a href="#rid10">10-12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>N-telopeptide (NTX) is the pyridinoline crosslink in the N-telopeptide region that joins alpha-1 chains to alpha-2 chains [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>C-telopeptide (CTX) is a fragment of the alpha-1 peptide with an isomerized bond between the aspartate and the glycine from the C-telopeptide region [<a href="#rid13">13</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h1">MARKERS OF BONE TURNOVER</span><span class="headingEndMark"> — </span>Urinary N-telopeptide crosslink (NTX) and serum C-telopeptide crosslink (CTX) are widely regarded as the most clinically useful markers of bone resorption, while bone-specific alkaline phosphatase (BSAP) and amino-terminal propeptide of type I procollagen (PINP) are the most clinically useful markers of bone formation [<a href="#rid14">14,15</a>].</p><p>The normal process of bone resorption results in the liberation of bone mineral and osteoid (which is composed mostly of collagen). The latter is not completely digested to its amino acid constituents, but to peptides that can be measured in serum and urine  (<a class="graphic graphic_table graphicRef77322" href="/z/d/graphic/77322.html" rel="external">table 1</a>). The total quantity of these peptides reflects the rate of bone resorption. Similarly, osteoid formation leads to the production of byproducts of collagen and other proteins as they mature and are rearranged to form osteoid. Some of these substances are released into the circulation. Thus, measurement of their serum concentrations can provide information about the rate of bone formation  (<a class="graphic graphic_table graphicRef77322" href="/z/d/graphic/77322.html" rel="external">table 1</a>) [<a href="#rid5">5,16</a>].</p><p>The serum concentration of BSAP and osteocalcin reflect the cellular activity of osteoblasts [<a href="#rid5">5,8,17,18</a>]. The serum concentration of the carboxy-terminal and amino-terminal propeptides of type I procollagen (PICP and PINP, respectively) reflects changes in synthesis of new collagen. The PINP measurement appears to be more specific than PICP for synthesis of bone collagen [<a href="#rid14">14</a>].</p><p>Urinary and serum concentrations of collagen crosslinks reflect bone resorption but not dietary intake. As a result, these substances are better indicators of bone resorption than urinary calcium or hydroxyproline excretion [<a href="#rid19">19</a>]. Furthermore, because deoxypyridinoline (D-PYR) and the peptide-bound alpha-1 to alpha-2 NTX and CTX are almost exclusively derived from collagen in bone, measurements of these substances are specific markers of bone resorption [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Assay variability</span><span class="headingEndMark"> — </span>There are many different ways to measure these metabolites of collagen. Although the original assays for collagen crosslinks required high-performance liquid chromatography (HPLC), antibodies have been raised to various regions of the pyridinoline crosslinks, and these substances can now be measured in serum or urine by immunoassays [<a href="#rid6">6,21-27</a>]. Serum assays tend to have less intraindividual variability than urine assays (10 versus 20 percent) [<a href="#rid1">1,28</a>].</p><p>Assay variability and poor standardization have limited the use of bone turnover markers (BTMs) in clinical practice [<a href="#rid29">29</a>]. However, several immunoassays have been automated, which improves reproducibility. In addition, normative values for premenopausal women are more rigorously established [<a href="#rid25">25,30</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Biologic variability</span><span class="headingEndMark"> — </span>In addition to assay variability, there are a number of physiologic conditions that increase or decrease bone turnover and, therefore, alter BTMs  (<a class="graphic graphic_table graphicRef68633" href="/z/d/graphic/68633.html" rel="external">table 2</a>). These factors must be considered when interpreting laboratory results [<a href="#rid31">31,32</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>There is a diurnal variation in bone turnover and a strong circadian rhythm to several indices of bone remodeling. The serum concentration or urinary excretion of most markers peaks around 6 AM and nadirs around 6 PM [<a href="#rid33">33-36</a>]. The only marker that is not influenced by diurnal variation is serum BSAP [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower body mass index (BMI) and smoking are associated with higher bone turnover and, therefore, higher BTMs [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>BTMs are increased around the time of ovulation [<a href="#rid38">38-40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recent food consumption suppresses BTMs [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exercise and physical activity may be associated with decreased bone turnover (lower BTMs) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone remodeling is important for fracture healing. BTMs remain elevated for up to four months after fracture [<a href="#rid43">43,44</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Practical aspects of measurement</span><span class="headingEndMark"> — </span>Because bone turnover and BTMs follow a circadian rhythm and are altered by food intake, urine measurements of BTMs should be collected as second morning fasting samples, and serum samples should be collected in the morning after an overnight fast [<a href="#rid45">45-47</a>]. Because BTM results vary with different laboratories, patients should have all of their measurements performed in the same laboratory.</p><p class="headingAnchor" id="H9"><span class="h1">VALIDATION OF MARKERS OF BONE TURNOVER</span><span class="headingEndMark"> — </span>As noted above, many substances are released from bone during the processes of resorption and formation. However, several criteria must be fulfilled for a particular measurement to have value as a marker of bone turnover (BTMs):</p><p class="bulletIndent1"><span class="glyph">●</span>The substance must change in parallel with changes in bone turnover as measured by histomorphometry [<a href="#rid3">3</a>] and calcium kinetics [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The serum concentration or urinary excretion of the substance must be high in conditions characterized by high bone turnover, such as hyperparathyroidism, hyperthyroidism, and Paget disease of bone [<a href="#rid1">1,49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The serum concentration or urinary excretion of the substance must be low in conditions characterized by low bone turnover, as occurs after the administration of antiresorptive drugs.</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Correlation of markers with histomorphometry and calcium kinetics</span><span class="headingEndMark"> — </span>Bone biopsies are expensive and invasive, and there are few studies correlating bone histology with BTMs. The correlations were adequate in the studies performed. In one report, as an example, the correlation coefficients between the results of histomorphometric measurements of bone resorption and urinary excretion of hydroxyproline, pyridinoline, and deoxypyridinoline (D-PYR) were 0.22, 0.77, and 0.80, respectively [<a href="#rid50">50</a>]. In other studies, correlation coefficients between the results of histomorphometric measurements of bone formation and serum cross-linked carboxy-terminal telopeptide of type I collagen (ICTP), serum carboxy-terminal propeptide of type 1 collagen (PICP), and serum osteocalcin were 0.61 [<a href="#rid51">51</a>], 0.77 [<a href="#rid52">52</a>], and 0.79 [<a href="#rid51">51</a>], respectively.</p><p>Studies of calcium kinetics are tedious and cumbersome but provide very accurate measurements of bone formation. In one study, as an example, most markers were very highly correlated (r = 0.9) with calcium accretion [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Elevation of markers in conditions characterized by increased bone turnover</span><span class="headingEndMark"> — </span>The available BTMs are high in conditions characterized by increased bone turnover, but the extent of the elevations varies considerably.</p><p class="bulletIndent1"><span class="glyph">●</span>The values for most markers are high in patients with hyperthyroidism [<a href="#rid23">23,53,54</a>], hyperparathyroidism [<a href="#rid53">53,55,56</a>], and in postmenopausal women [<a href="#rid17">17,53,57</a>]; serum C-telopeptide crosslink (CTX) and urinary N-telopeptide crosslink (NTX) values tend to increase more at menopause than the pyridinolines [<a href="#rid15">15,46,58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients with Paget disease [<a href="#rid59">59-61</a>] or osseous metastases [<a href="#rid62">62-67</a>] have high values for most tests, but serum osteocalcin concentrations are often normal [<a href="#rid61">61,62</a>]. Urinary NTX excretion and serum BSAP and (amino-terminal propeptide of type I procollagen) PINP are the most sensitive indicators of turnover in patients with Paget disease [<a href="#rid59">59,65,68,69</a>]. (See  <a class="medical medical_review" href="/z/d/html/5596.html" rel="external">"Treatment of Paget disease of bone", section on 'Monitoring'</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Decline in markers after antiresorptive therapy</span><span class="headingEndMark"> — </span>The serum concentrations or urinary excretion of most BTMs fall during antiresorptive therapy. The extent of the reduction, however, depends upon both the therapy and the marker. As an example, in postmenopausal women treated with bisphosphonates or menopausal hormone therapy, urinary NTX decreased to a greater extent in the <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> group compared with the hormone therapy group [<a href="#rid70">70</a>]. However, BSAP decreased similarly in both groups, and the decrease in osteocalcin was greater in the hormone therapy group.</p><p>Several trials have shown an association between the decrease in BTMs after initiation of antiresorptive therapy and long-term antifracture efficacy. These trials are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2041.html" rel="external">"Use of biochemical markers of bone turnover in osteoporosis", section on 'Osteoporosis therapy'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone turnover markers</strong> – Biochemical markers of bone turnover (BTMs) reflect rates of bone resorption and bone formation  (<a class="graphic graphic_table graphicRef77322" href="/z/d/graphic/77322.html" rel="external">table 1</a>). (See <a class="local">'Bone remodeling'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measurement </strong>– BTMs are not widely used in clinical practice because of analytical and biological variability  (<a class="graphic graphic_table graphicRef68633" href="/z/d/graphic/68633.html" rel="external">table 2</a>). When they are used in clinical practice, measurements should be made under standardized conditions using the same laboratory for a given patient. In addition, biological variability should be considered when interpreting BTM results. (See <a class="local">'Markers of bone turnover'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical utility </strong>– Urinary N-telopeptide crosslink (NTX) and serum C-telopeptide crosslink (CTX) are widely regarded as the most clinically useful markers of bone resorption, while bone-specific alkaline phosphatase (BSAP) and amino-terminal propeptide of type I procollagen (PINP) are the most clinically useful markers of bone formation. (See <a class="local">'Markers of bone turnover'</a> above.)</p><p></p><p class="bulletIndent1">The clinical utility of BTMs in monitoring the response to osteoporosis therapy is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2041.html" rel="external">"Use of biochemical markers of bone turnover in osteoporosis"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 2009; 24:561.</a></li><li><a class="nounderline abstract_t">Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 1996; 17:333.</a></li><li><a class="nounderline abstract_t">Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2:595.</a></li><li><a class="nounderline abstract_t">Scheven BA, Visser JW, Nijweide PJ. In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population. Nature 1986; 321:79.</a></li><li><a class="nounderline abstract_t">Taylor AK, Lueken SA, Libanati C, Baylink DJ. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am 1994; 20:589.</a></li><li><a class="nounderline abstract_t">Hanson DA, Weis MA, Bollen AM, et al. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992; 7:1251.</a></li><li><a class="nounderline abstract_t">Garnero P, Gineyts E, Arbault P, et al. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995; 10:641.</a></li><li><a class="nounderline abstract_t">Gomez B Jr, Ardakani S, Ju J, et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995; 41:1560.</a></li><li><a class="nounderline abstract_t">Horgan DJ, King NL, Kurth LB, Kuypers R. Collagen crosslinks and their relationship to the thermal properties of calf tendons. Arch Biochem Biophys 1990; 281:21.</a></li><li><a class="nounderline abstract_t">Eyre DR, Koob TJ, Van Ness KP. Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Anal Biochem 1984; 137:380.</a></li><li><a class="nounderline abstract_t">Robins, SP. Collagen crosslinks in metabolic bone disease. Acta Orthop Scand 1995; 66:171.</a></li><li><a class="nounderline abstract_t">Eyre DR, Dickson IR, Van Ness K. Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues. Biochem J 1988; 252:495.</a></li><li><a class="nounderline abstract_t">Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 1998; 44:2290.</a></li><li><a class="nounderline abstract_t">Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998; 13:1124.</a></li><li><a class="nounderline abstract_t">Fink E, Cormier C, Steinmetz P, et al. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 2000; 11:295.</a></li><li class="breakAll">Szulc P, Delmas PD. Biochemical markers of bone turnover in osteoporosis. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Rosen CJ (Ed), ASBMR, 2008. p.174.</li><li><a class="nounderline abstract_t">Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993; 77:1046.</a></li><li><a class="nounderline abstract_t">Hill CS, Wolfert RL. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chim Acta 1990; 186:315.</a></li><li><a class="nounderline abstract_t">Eyre D. New biomarkers of bone resorption. J Clin Endocrinol Metab 1992; 74:470A.</a></li><li><a class="nounderline abstract_t">Rosen HN, Dresner-Pollak R, Moses AC, et al. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 1994; 54:26.</a></li><li><a class="nounderline abstract_t">Eastell R, Mallinak N, Weiss S, et al. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000; 15:594.</a></li><li><a class="nounderline abstract_t">Risteli J, Elomaa I, Niemi S, et al. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39:635.</a></li><li><a class="nounderline abstract_t">Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994; 79:780.</a></li><li><a class="nounderline abstract_t">Rosenquist C, Fledelius C, Christgau S, et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998; 44:2281.</a></li><li><a class="nounderline abstract_t">Glover SJ, Gall M, Schoenborn-Kellenberger O, et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 2009; 24:389.</a></li><li><a class="nounderline abstract_t">Melkko J, Kauppila S, Niemi S, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996; 42:947.</a></li><li><a class="nounderline abstract_t">Halleen JM, Alatalo SL, Suominen H, et al. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000; 15:1337.</a></li><li><a class="nounderline abstract_t">Scariano JK, Garry PJ, Montoya GD, et al. Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre- and postmenopausal women. Clin Biochem 2001; 34:639.</a></li><li><a class="nounderline abstract_t">Seibel MJ, Lang M, Geilenkeuser WJ. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001; 47:1443.</a></li><li><a class="nounderline abstract_t">de Papp AE, Bone HG, Caulfield MP, et al. A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 2007; 40:1222.</a></li><li><a class="nounderline abstract_t">Pagani F, Francucci CM, Moro L. Markers of bone turnover: biochemical and clinical perspectives. J Endocrinol Invest 2005; 28:8.</a></li><li><a class="nounderline abstract_t">Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000; 11 Suppl 6:S30.</a></li><li><a class="nounderline abstract_t">Hassager C, Risteli J, Risteli L, et al. Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J Bone Miner Res 1992; 7:1307.</a></li><li><a class="nounderline abstract_t">Schlemmer A, Hassager C, Jensen SB, Christiansen C. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 1992; 74:476.</a></li><li><a class="nounderline abstract_t">Christgau S. Circadian variation in serum CrossLaps concentration is reduced in fasting individuals. Clin Chem 2000; 46:431.</a></li><li><a class="nounderline abstract_t">Bollen AM, Martin MD, Leroux BG, Eyre DR. Circadian variation in urinary excretion of bone collagen cross-links. J Bone Miner Res 1995; 10:1885.</a></li><li><a class="nounderline abstract_t">Glover SJ, Garnero P, Naylor K, et al. Establishing a reference range for bone turnover markers in young, healthy women. Bone 2008; 42:623.</a></li><li><a class="nounderline abstract_t">Adami S, Bianchi G, Brandi ML, et al. Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int 2008; 82:341.</a></li><li><a class="nounderline abstract_t">Gorai I, Taguchi Y, Chaki O, et al. Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle. J Clin Endocrinol Metab 1998; 83:326.</a></li><li><a class="nounderline abstract_t">Garnero P, Sornay-Rendu E, Delmas PD. Decreased bone turnover in oral contraceptive users. Bone 1995; 16:499.</a></li><li><a class="nounderline abstract_t">Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18:2180.</a></li><li><a class="nounderline abstract_t">Woitge HW, Friedmann B, Suttner S, et al. Changes in bone turnover induced by aerobic and anaerobic exercise in young males. J Bone Miner Res 1998; 13:1797.</a></li><li><a class="nounderline abstract_t">Ivaska KK, Gerdhem P, Akesson K, et al. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res 2007; 22:1155.</a></li><li><a class="nounderline abstract_t">Stoffel K, Engler H, Kuster M, Riesen W. Changes in biochemical markers after lower limb fractures. Clin Chem 2007; 53:131.</a></li><li><a class="nounderline abstract_t">Garnero P, Grimaux M, Seguin P, Delmas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994; 9:255.</a></li><li><a class="nounderline abstract_t">Uebelhart D, Schlemmer A, Johansen JS, et al. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991; 72:367.</a></li><li><a class="nounderline abstract_t">Bauer DC. Clinical Use of Bone Turnover Markers. JAMA 2019; 322:569.</a></li><li><a class="nounderline abstract_t">Weaver CM, Peacock M, Martin BR, et al. Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy females. J Bone Miner Res 1997; 12:1714.</a></li><li><a class="nounderline abstract_t">Benker G, Breuer N, Windeck R, Reinwein D. Calcium metabolism in thyroid disease. J Endocrinol Invest 1988; 11:61.</a></li><li><a class="nounderline abstract_t">Delmas PD, Schlemmer A, Gineyts E, et al. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991; 6:639.</a></li><li><a class="nounderline abstract_t">Eriksen EF, Charles P, Melsen F, et al. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 1993; 8:127.</a></li><li><a class="nounderline abstract_t">Parfitt AM, Simon LS, Villanueva AR, Krane SM. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987; 2:427.</a></li><li><a class="nounderline abstract_t">Cheung CK, Panesar NS, Haines C, et al. Immunoassay of a tartrate-resistant acid phosphatase in serum. Clin Chem 1995; 41:679.</a></li><li><a class="nounderline abstract_t">Ohishi T, Takahashi M, Kushida K, et al. Quantitative analyses of urinary pyridinoline and deoxypyridinoline excretion in patients with hyperthyroidism. Endocr Res 1992; 18:281.</a></li><li><a class="nounderline abstract_t">Seibel MJ, Gartenberg F, Silverberg SJ, et al. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 1992; 74:481.</a></li><li><a class="nounderline abstract_t">De la Piedra C, Díaz Martín MA, Díaz Diego EM, et al. Serum concentrations of carboxyterminal cross-linked telopeptide of type I collagen (ICTP), serum tartrate resistant acid phosphatase, and serum levels of intact parathyroid hormone in parathyroid hyperfunction. Scand J Clin Lab Invest 1994; 54:11.</a></li><li><a class="nounderline abstract_t">Hassager C, Colwell A, Assiri AM, et al. Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. Clin Endocrinol (Oxf) 1992; 37:45.</a></li><li><a class="nounderline abstract_t">Bonde M, Qvist P, Fledelius C, et al. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995; 80:864.</a></li><li><a class="nounderline abstract_t">Randall AG, Kent GN, Garcia-Webb P, et al. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links. J Bone Miner Res 1996; 11:1176.</a></li><li><a class="nounderline abstract_t">Blumsohn A, Naylor KE, Assiri AM, Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem 1995; 41:1592.</a></li><li><a class="nounderline abstract_t">Alvarez L, Guañabens N, Peris P, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 1995; 10:458.</a></li><li><a class="nounderline abstract_t">Nakayama K, Fukumoto S, Takeda S, et al. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 1996; 81:607.</a></li><li><a class="nounderline abstract_t">Abildgaard N, Nielsen JL, Heickendorff L. Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan. Am J Hematol 1994; 46:173.</a></li><li><a class="nounderline abstract_t">Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992; 66:337.</a></li><li><a class="nounderline abstract_t">Demers LM, Costa L, Chinchilli VM, et al. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995; 41:1489.</a></li><li><a class="nounderline abstract_t">Body JJ, Delmas PD. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 1992; 74:471.</a></li><li><a class="nounderline abstract_t">Cooper EH, Whelan P, Purves D. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer. Prostate 1994; 25:236.</a></li><li><a class="nounderline abstract_t">Alvarez L, RicOs C, Peris P, et al. Components of biological variation of biochemical markers of bone turnover in Paget's bone disease. Bone 2000; 26:571.</a></li><li><a class="nounderline abstract_t">Alvarez L, Guañabens N, Peris P, et al. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease. Bone 2001; 29:447.</a></li><li><a class="nounderline abstract_t">Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2005; 90:2762.</a></li></ol></div><div id="topicVersionRevision">Topic 2047 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19257812" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8854049" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Molecular basis and clinical application of biological markers of bone turnover.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3455637" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3754620" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7984780" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Biochemical markers of bone turnover for the clinical assessment of bone metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1466251" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7610936" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586543" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2383022" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Collagen crosslinks and their relationship to the thermal properties of calf tendons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6731820" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Collagen crosslinks in metabolic bone disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3415669" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9799756" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9661076" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928218" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928218" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8104954" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2178811" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1740477" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : New biomarkers of bone resorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8118749" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10750575" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8472358" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8077361" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9799755" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18665786" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8665688" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Immunoassay for intact amino-terminal propeptide of human type I procollagen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893682" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849624" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre- and postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11468235" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Interlaboratory variation of biochemical markers of bone turnover.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17331821" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A cross-sectional study of bone turnover markers in healthy premenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16550716" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Markers of bone turnover: biochemical and clinical perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11193238" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Preanalytical variability of biochemical markers of bone turnover.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1466255" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1740479" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10702538" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Circadian variation in serum CrossLaps concentration is reduced in fasting individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8619368" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Circadian variation in urinary excretion of bone collagen cross-links.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18289953" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Establishing a reference range for bone turnover markers in young, healthy women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18470550" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Determinants of bone turnover markers in healthy premenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9467535" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7654464" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Decreased bone turnover in oral contraceptive users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14672353" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Role of gastrointestinal hormones in postprandial reduction of bone resorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9844096" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Changes in bone turnover induced by aerobic and anaerobic exercise in young males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17488197" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17130179" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Changes in biochemical markers after lower limb fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8140939" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1991806" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31294761" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical Use of Bone Turnover Markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9333133" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3283206" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Calcium metabolism in thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1887826" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8442431" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3455625" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7729045" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Immunoassay of a tartrate-resistant acid phosphatase in serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1473521" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Quantitative analyses of urinary pyridinoline and deoxypyridinoline excretion in patients with hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1740480" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8171266" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Serum concentrations of carboxyterminal cross-linked telopeptide of type I collagen (ICTP), serum tartrate resistant acid phosphatase, and serum levels of intact parathyroid hormone in parathyroid hyperfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1424192" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7883844" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8854254" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586548" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7785468" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636276" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8192146" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1503907" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586522" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Biochemical markers of bone turnover in patients with metastatic bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1740478" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7526352" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10831927" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Components of biological variation of biochemical markers of bone turnover in Paget's bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704497" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15713726" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
